Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway.
Animals
Carcinoma, Hepatocellular
/ genetics
Cell Line, Tumor
Cell Proliferation
Gene Expression Regulation, Neoplastic
Hep G2 Cells
Humans
Liver Neoplasms
/ genetics
Mice
Minichromosome Maintenance Complex Component 3
/ genetics
NF-kappa B
/ metabolism
Phosphorylation
Prognosis
Radiation Tolerance
Signal Transduction
Up-Regulation
HCC
MCM3
NF-κB pathway
Radiotherapy resistance
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
17 Jun 2019
17 Jun 2019
Historique:
received:
09
02
2019
accepted:
22
05
2019
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
4
12
2019
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common tumors in the worldwide, it develops resistance to radiotherapy during treatment, understanding the regulatory mechanisms of radioresistance generation is the urgent need for HCC therapy. qRT-PCR, western blot and immunohistochemistry were used to examine MCM3 expression. MTT assay, colony formation assay, terminal deoxynucleotidyl transferase nick end labeling assay and In vivo xenograft assay were used to determine the effect of MCM3 on radioresistance. Gene set enrichment analysis, luciferase reporter assay, western blot and qRT-PCR were used to examine the effect of MCM3 on NF-κB pathway. We found DNA replication initiation protein Minichromosome Maintenance 3 (MCM3) was upregulated in HCC tissues and cells, patients with high MCM3 expression had poor outcome, it was an independent prognostic factor for HCC. Cells with high MCM3 expression or MCM3 overexpression increased the radioresistance determined by MTT assay, colony formation assay, TUNEL assay and orthotopic transplantation mouse model, while cells with low MCM3 expression or MCM3 knockdown reduced the radioresistance. Mechanism analysis showed MCM3 activated NF-κB pathway, characterized by increasing the nuclear translocation of p65, the expression of the downstream genes NF-κB pathway and the phosphorylation of IKK-β and IκBα. Inhibition of NF-κB in MCM3 overexpressing cells using small molecular inhibitor reduced the radioresistance, suggesting MCM3 increased radioresistance through activating NF-κB pathway. Moreover, we found MCM3 expression positively correlated with NF-κB pathway in clinic. Our findings revealed that MCM3 promoted radioresistance through activating NF-κB pathway, strengthening the role of MCM subunits in the tumor progression and providing a new target for HCC therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is the most common tumors in the worldwide, it develops resistance to radiotherapy during treatment, understanding the regulatory mechanisms of radioresistance generation is the urgent need for HCC therapy.
METHODS
METHODS
qRT-PCR, western blot and immunohistochemistry were used to examine MCM3 expression. MTT assay, colony formation assay, terminal deoxynucleotidyl transferase nick end labeling assay and In vivo xenograft assay were used to determine the effect of MCM3 on radioresistance. Gene set enrichment analysis, luciferase reporter assay, western blot and qRT-PCR were used to examine the effect of MCM3 on NF-κB pathway.
RESULTS
RESULTS
We found DNA replication initiation protein Minichromosome Maintenance 3 (MCM3) was upregulated in HCC tissues and cells, patients with high MCM3 expression had poor outcome, it was an independent prognostic factor for HCC. Cells with high MCM3 expression or MCM3 overexpression increased the radioresistance determined by MTT assay, colony formation assay, TUNEL assay and orthotopic transplantation mouse model, while cells with low MCM3 expression or MCM3 knockdown reduced the radioresistance. Mechanism analysis showed MCM3 activated NF-κB pathway, characterized by increasing the nuclear translocation of p65, the expression of the downstream genes NF-κB pathway and the phosphorylation of IKK-β and IκBα. Inhibition of NF-κB in MCM3 overexpressing cells using small molecular inhibitor reduced the radioresistance, suggesting MCM3 increased radioresistance through activating NF-κB pathway. Moreover, we found MCM3 expression positively correlated with NF-κB pathway in clinic.
CONCLUSIONS
CONCLUSIONS
Our findings revealed that MCM3 promoted radioresistance through activating NF-κB pathway, strengthening the role of MCM subunits in the tumor progression and providing a new target for HCC therapy.
Identifiants
pubmed: 31208444
doi: 10.1186/s13046-019-1241-9
pii: 10.1186/s13046-019-1241-9
pmc: PMC6580494
doi:
Substances chimiques
MCM3 protein, human
0
NF-kappa B
0
Minichromosome Maintenance Complex Component 3
EC 3.6.4.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
263Subventions
Organisme : National Natural Science Foundation of China
ID : 81602701
Organisme : the Natural Science Foundation of China
ID : 81760496
Organisme : Natural Science Foundation of Guangdong Province
ID : 2016A030313195
Organisme : Natural Science Foundation of Guangdong Province
ID : 2014A030313131
Organisme : Natural Science Foundation of Guangdong Province
ID : 2017A030313547
Organisme : Natural Science Foundation of Guangdong Province
ID : 2018A030313176
Organisme : Key Scientific and Technological Projects of Guangdong Province
ID : 2014B020228003
Organisme : Key Scientific and Technological Projects of Guangdong Province
ID : 2015A070710006
Organisme : Key Scientific and Technological Projects of Guangdong Province
ID : 2016A020215053
Organisme : Key Scientific and Technological Projects of Guangdong Province
ID : 2014B030301041
Organisme : Science and Technology Planning Project of Guangzhou
ID : 201400000001-3
Organisme : Science and Technology Planning Project of Guangzhou
ID : 158100076
Organisme : Ministry of Science and Technology (VN)
ID : 201507020037
Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Références
J Mol Biol. 2004 Jul 23;340(5):1197-206
pubmed: 15236977
Clin Cancer Res. 2005 Jan 1;11(1):249-58
pubmed: 15671553
Cancer Cell. 2008 Feb;13(2):153-66
pubmed: 18242515
Exp Mol Pathol. 2010 Feb;88(1):138-42
pubmed: 19818763
Oncogene. 2010 Oct 7;29(40):5475-89
pubmed: 20661220
Mol Cancer. 2011 Jan 28;10(1):10
pubmed: 21276221
Diagn Pathol. 2012 Jul 17;7:82
pubmed: 22805320
Clin Cancer Res. 2012 Sep 15;18(18):4997-5007
pubmed: 22811581
Annu Rev Biophys. 2013;42:443-68
pubmed: 23495970
J Clin Invest. 2013 May;123(5):1911-8
pubmed: 23635789
Asian Pac J Cancer Prev. 2013;14(6):3479-82
pubmed: 23886132
Int J Hepatol. 2013;2013:419302
pubmed: 24455285
J Transl Med. 2014 Jul 15;12:196
pubmed: 25023649
BMC Cancer. 2014 Jul 21;14:526
pubmed: 25046975
Genes Dev. 2014 Aug 1;28(15):1653-66
pubmed: 25085418
Mol Cell. 2014 Sep 4;55(5):655-65
pubmed: 25087876
Int J Oncol. 2015 May;46(5):2057-66
pubmed: 25738261
Nat Rev Mol Cell Biol. 2015 Jun;16(6):360-74
pubmed: 25999062
Protein Cell. 2016 Feb;7(2):89-99
pubmed: 26349457
PLoS One. 2015 Oct 07;10(10):e0137703
pubmed: 26444992
Anticancer Res. 2015 Nov;35(11):6017-26
pubmed: 26504025
Cell Metab. 2016 Jan 12;23(1):206-19
pubmed: 26724859
Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):120-125
pubmed: 27258565
Oncotarget. 2016 Aug 23;7(34):55555-55571
pubmed: 27487130
Rom J Morphol Embryol. 2016;57(2):407-12
pubmed: 27516012
Sci Rep. 2016 Sep 02;6:31963
pubmed: 27585821
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cell Death Dis. 2017 Feb 9;8(2):e2603
pubmed: 28182015
Oncotarget. 2017 Jun 13;8(24):39209-39217
pubmed: 28424404
Oncotarget. 2017 Apr 18;8(16):26380-26393
pubmed: 28460433
Oncotarget. 2017 Apr 18;8(16):27263-27276
pubmed: 28460481
Pol J Pathol. 2016;67(4):351-356
pubmed: 28547962
J Cell Mol Med. 2017 Nov;21(11):2872-2883
pubmed: 28557284
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Cancer Lett. 2017 Dec 28;411:150-161
pubmed: 28989054
Cancer Cell Int. 2017 Oct 24;17:97
pubmed: 29089860
J Exp Clin Cancer Res. 2018 Jan 22;37(1):10
pubmed: 29357919
Cancer. 2018 Sep 1;124(17):3476-3489
pubmed: 29645076
Trends Cancer. 2018 Nov;4(11):755-768
pubmed: 30352678
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):40-49
pubmed: 30419317
EBioMedicine. 2018 Dec;38:113-126
pubmed: 30429088
J Clin Invest. 2019 Feb 1;129(2):676-693
pubmed: 30481162
Exp Cell Res. 2019 Jan 1;374(1):152-161
pubmed: 30496760